Creating new drugs to treat neuropathic pain
Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain
This study is exploring a new medication to help people with neuropathic pain by targeting a specific enzyme that affects pain signals, aiming to create a treatment that works better and has fewer side effects than current options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | 4e Therapeutics INC. NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-10684818 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of medication called MNK inhibitors to help manage neuropathic pain, which is often difficult to treat. The approach involves understanding how MNK, a specific enzyme, affects pain signals in the nervous system, particularly after nerve injuries or inflammation. By optimizing existing compounds, like eFT508, the researchers aim to create a more effective treatment that minimizes side effects, such as depression, which can occur with current options. Patients with neuropathic pain may benefit from this innovative approach that targets the underlying mechanisms of their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing neuropathic pain due to conditions like nerve injury or chronic pain syndromes.
Not a fit: Patients with pain not related to neuropathic mechanisms or those who do not respond to pain management therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from neuropathic pain.
How similar studies have performed: Previous research has shown promise with similar MNK inhibitors in other contexts, but this specific application for neuropathic pain is relatively novel.
Where this research is happening
Austin, United States
- 4e Therapeutics INC. — Austin, United States (Active)
Researchers
- Principal investigator: Sahn, James Jeffrey — 4e Therapeutics INC.
- Study coordinator: Sahn, James Jeffrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.